These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 19166444)

  • 1. Switching from NPH insulin to once-daily insulin detemir in basal-bolus-treated patients with diabetes mellitus: data from the European cohort of the PREDICTIVE study.
    Sreenan S; Virkamäki A; Zhang K; Hansen JB;
    Int J Clin Pract; 2008 Dec; 62(12):1971-80. PubMed ID: 19166444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching patients from insulin glargine-based basal-bolus regimens to a once daily insulin detemir-based basal-bolus regimen: results from a subgroup of the PREDICTIVE study.
    Yenigun M; Honka M
    Int J Clin Pract; 2009 Mar; 63(3):425-32. PubMed ID: 19222627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.
    Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
    Pediatr Diabetes; 2011 Nov; 12(7):632-41. PubMed ID: 21418455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Honka M; Ackermann RW; Meriläinen M; Gallwitz B; Sreenan S;
    Curr Med Res Opin; 2008 Feb; 24(2):369-76. PubMed ID: 18096110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
    J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial.
    Bartley PC; Bogoev M; Larsen J; Philotheou A
    Diabet Med; 2008 Apr; 25(4):442-9. PubMed ID: 18387078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR; Gilbert RE; Yue DK
    Intern Med J; 2005 Sep; 35(9):536-42. PubMed ID: 16105155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.
    Home P; Bartley P; Russell-Jones D; Hanaire-Broutin H; Heeg JE; Abrams P; Landin-Olsson M; Hylleberg B; Lang H; Draeger E;
    Diabetes Care; 2004 May; 27(5):1081-7. PubMed ID: 15111525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K; Ross GP; Pavlic-Renar I; Perriello G; Philotheou A; Jendle J; Gall MA; Heller SR
    Diabet Med; 2006 Jul; 23(7):729-35. PubMed ID: 16842476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2).
    Kanazawa Y; Igarashi Y; Komiya K; Sakurai Y; Shimizu T; Fujitani Y; Tanaka Y; Watada H; Kawamori R; Hirose T
    Endocr J; 2007 Dec; 54(6):975-83. PubMed ID: 18000343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin detemir improves glycemic control and reduces hypoglycemia in children with type 1 diabetes: findings from the Turkish cohort of the PREDICTIVE observational study.
    Kurtoglu S; Atabek ME; Dizdarer C; Pirgon O; Isguven P; Emek S;
    Pediatr Diabetes; 2009 Sep; 10(6):401-7. PubMed ID: 19220776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
    Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
    J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials.
    Garber AJ; Clauson P; Pedersen CB; Kølendorf K
    J Am Geriatr Soc; 2007 Nov; 55(11):1735-40. PubMed ID: 17979896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I; Vague P; Selam JL; Skeie S; Lang H; Draeger E; Elte JW
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
    Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H; Watanabe Y; Ueki A; Ohno A; Kato M; Kondo K; Takamura H; Takesue M; Nishimura H; Matsuda D; Miyakawa T
    Int J Clin Pract; 2010 Oct; 64(11):1512-1519. PubMed ID: 20678116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin.
    Pieber TR; Draeger E; Kristensen A; Grill V
    Diabet Med; 2005 Jul; 22(7):850-7. PubMed ID: 15975098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes.
    Standl E; Lang H; Roberts A
    Diabetes Technol Ther; 2004 Oct; 6(5):579-88. PubMed ID: 15628811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.